Levetiracetam injection is indicated for adjunctive therapy as an alternative when oral administration is not feasible. It is used to treat partial onset seizures in patients one month of age and older with epilepsy, myoclonic seizures in patients 12 years and older with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in patients six years and older with idiopathic generalized epilepsy.
Mechanism of Action
The precise mechanism of action is unknown. Animal studies show levetiracetam protects against secondary generalized activity from focal seizures, and inhibits burst firing in the hippocampus. In vitro studies demonstrate that levetiracetam opposes the activity of negative modulators of GABA- and glycine-gated currents and partially inhibits N-type calcium currents. A saturable and stereoselective neuronal binding site for levetiracetam has been identified as the synaptic vesicle protein SV2A, which correlates with the drug’s antiseizure activity.
Dosage and Administration
Clinical studies utilizing oral formulations have established levetiracetam’s effectiveness as adjunctive therapy in adults with refractory partial onset seizures. Dosage is individualized, with typical intravenous administration ranging from 500 to 1,500 mg every 12 hours, adjusted based on seizure frequency and patient condition. Supplemental doses are recommended for patients undergoing dialysis.